Monoamine oxidase inhibitors in depression treatment: Addressing gaps and future directions.
Published In: Acta Psychiatrica Scandinavica, 2024, v. 150, n. 6. P. 573 1 of 3
Database: Academic Search Ultimate 2 of 3
Authored By: Lee, Jen‐Chin; Wei, Lien‐Chung 3 of 3
Abstract
The article in Acta Psychiatrica Scandinavica discusses the efficacy and tolerability of monoamine oxidase inhibitors (MAOIs) in treating depressive episodes in mood disorders. While the review found similar efficacy between MAOIs and other antidepressants, previous studies suggest potential superiority of MAOIs in certain patient subgroups. The article highlights the need for further research on MAOIs in atypical depression and treatment-resistant depression (TRD), as well as exploring barriers to their use in clinical practice. Overall, the meta-analysis emphasizes the importance of continued research to optimize the use of MAOIs in depression treatment. [Extracted from the article]
Additional Information
- Source:Acta Psychiatrica Scandinavica. 2024/12, Vol. 150, Issue 6, p573
- Document Type:Article
- Subject Area:Biology
- Publication Date:2024
- ISSN:0001-690X
- DOI:10.1111/acps.13740
- Accession Number:180622740
- Copyright Statement:Copyright of Acta Psychiatrica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Looking to go deeper into this topic? Look for more articles on EBSCOhost.